Edaravone May Prevent Ferroptosis in ALS by Spasić, Snežana et al.
Send Orders for Reprints to reprints@benthamscience.net 
Current Drug Targets, 2020, 21, 000-000 1 
REVIEW ARTICLE 
1389-4501/20 $65.00+.00 
Edaravone May Prevent Ferroptosis in ALS 
Snežana Spasić1,*, Aleksandra Nikolić-Kokić2, Srđan Miletić1, Zorana Oreščanin-Dušić2, Mihajlo B. 
Spasić2, Duško Blagojević2 and Zorica Stević3 
1Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Belgrade Serbia; 
2Department of Physiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Ser-
bia, University of Belgrade, Belgrade, Serbia; 3Clinic of Neurology, Clinical Center of Serbia, School of Medicine, Uni-
versity of Belgrade, Belgrade, Serbia 
Abstract: Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new 
treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifical-
ly targets oxidative damage interacting with lipid radicals in the cell. ALS is a disease that multiple 
cell types are involved in the devastating loss of motor neurons. Mutations and biochemical changes 
in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. 
The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor 
neu-rons have been reported to exhibit features of apoptosis. However, non-apoptotic features of 
dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the 
prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed. 
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Amyotrophic lateral sclerosis (ALS) is a form of motor 
neuron disease characterised by dying nerve cells. The result 
of which is significant patient disability and death. ALS is 
still an intractable motor neuron disease, despite at least 150 
years of research worldwide. In 1995, the Food and Drug 
Administration (FDA) approved Riluzole. It modulates glu-
tamate neurotransmission by inhibiting N-methyl-D-
aspartate receptors. Unfortunately, Riluzole’s impact on the 
disease is limited. The FDA recently approved Radicava™ 
(Edaravone) for the treatment of ALS. Even though several 
mutations underlying rare cases of familial ALS have been 
identified during the last decade, the pathogenesis of ALS 
remains poorly understood. Various mechanisms have been 
suggested to contribute to disease pathology such as exci-
totoxicity, oxidative stress, protein aggregation, inflamma-
tion, vascular endothelial growth factor deficit which leads 
to hypoxia and ferroptosis. Compelling evidence points 
nowadays towards ALS to be a multi-system disease. Both 
the appearance and the intensity of the disease is a combi-
nation of structural, physiological, and metabolic changes 
within the nervous system [1, 2]. As many ALS patients ex-
press extrapyramidal deficits, neuropathological findings 
fully support the notion of multisystem brain degeneration. 
To treat the multisystemic character of ALS therapeutically 
is a difficult task especially in the absence of reliable 
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biomarkers and a full understanding of the pathophysiologi-
cal mechanisms of the disease [3]. Recent results have con-
firmed that a combinatorial approach co-targeting different 
pathogenic mechanisms in independent cell types is a bene-
ficial therapeutic strategy for ALS [4].  
1.2. Main Pathogenic Mechanisms in ALS 
 Our previous investigations demonstrated that the cata-
lytic activity of iron in CSF is modulated by exogenous lig-
ands and that there could be some synergy between redox 
activities of iron and copper in the Fenton system in CSF [5]. 
Iron accumulation was observed in the CNS of ALS patients 
by magnetic resonance imaging [6]. More recently, accumu-
lated iron was detected in multiple brain regions, including 
the motor cortex, Substantia nigra, globus pallidus, red nu-
cleus, and the putamen in ALS patients by quantitative sus-
ceptibility mapping [7]. The pathogenic impact of iron me-
tabolism deregulation in ALS has been further supported by 
the partially protective effects of iron chelators in ALS 
mouse models [8]. The neuroprotection of iron chelation 
may result from the attenuation of iron-related oxidative 
stress, iron accumulation, and prevention of ferroptosis. 
There are clinical evidence about the neuroprotective 
potential of a therapeutically safe chelation treatment on 
early-stage amyotrophic lateral sclerosis (ALS) patients, 
which respond-ed significantly to treatment in both brain 
iron deposits and indicators of disease progression [9].  
 There have been historical attempts to treat ALS with 
antioxidants. All previous studies demonstrated that antioxi-
dants alone had no significant therapeutic effect in ALS pa-
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tients. Of interest are the findings in an ALS study group 
which showed that α-tocopherol alone had no effect on the 
deterioration of function assessed by the modified Norris 
limb scale [10]. Possible reasons are that α-tocopherol acts in 
the plasma membrane and is regenerated by vitamin C 
which has no effect on intracellular membranes. Apostolski 
and colleagues evaluated the effects of α-tocopherol in com-
bination with selenium, amino acids, and nimodipine, a cal-
cium ion channel blocker [11]. It is particularly important in 
the geographical regions deficient in selenium. 
 Recent results compared the Serbian population to the 
results reported in other population groups worldwide and 
some authors concluded that the Serbian population had 
signifi-cantly reduced content of Se (12). Selenium is also 
important as it supports the activity of glutathione 
peroxidase-4 (GPx4). GPx4 is also known as phospholipid 
hydroperoxide-glutathione peroxidase. Within the protein 
glutathione perox-idase family, GPx4 is the only enzyme 
with phospholipid hydroperoxydase activity, using 
glutathione as the reducing agent [13]. Decreased GPx4 
activity is also found to potenti-ate Ferroptosis. It seems that 
events that potentiate Ferroptosis are the main components 
in the induction of motoneuron death in ALS. 
1.3. Role of Edaravone 
 Edaravone is an antioxidant targeting oxidative damage 
particularly intracellular lipid membranes, but can also act in 
extracellular and intracellular compartments. This synthetic 
antioxidant molecule (Fig. 1) is able to quench hydroxyl, 
peroxyl, and superoxide radicals and showed antioxidant 
activity against lipid peroxidative damage induced by water- 
or lipid-soluble radicals [14, 15]. Oxidative stress-induced 
by Fe2+ increased production of hydoxil radicals (Fenton 
reaction) is the main cause of neuronal damage in ALS [16]. 
It is characterised by a significant increase in markers of 
DNA oxidative injury (including 8-hydroxy-2’-deoxyguano- 
sine) and in protein oxidation (for example, free 3-
nitrotyrosine and its metabolite 3-nitro-4-hydroxyphenol 
acetic acid) in CSF of ALS patients. Antioxidants have failed 
to limit increased oxidative damage in ALS patients. Contra-
ry to other antioxidants advantages and characteristics of 
Ederavone are: 
• Its pKa (7.0) is close to the physiological pH (7.4), and
Edaravone exists as both a neutral molecule and an anion in
the body [16]
• Edaravone anion exhibits potent radical-scavenging activity
via an electron-donating mechanism and can react with a
wide variety of radical species.
Edaravone is well distributed to both the aqueous phase 
where radicals are primarily generated and the lipid phase 
where lipid peroxidation proceeds by radical chain reaction 
via secondarily induced peroxyl radicals, and it should scav-
enge radicals in both environments [17]. Edaravone succeeds 
in overcoming the refractory mechanism to exogenous anti-
oxidants by expressing its anti-oxidative, lipid stabilising 
effects intracellularly, thereby preventing a process termed 
ferroptosis. There are data that indicate that Edaravone pos-
sesses antioxidant properties mainly due to its reactivity with 
free radicals, such as the hydroxyl radical (•OH) and perox-
ide radicals [18]. The possible mechanism behind Edara-
vones’s antioxidant capability is the transfer of electrons 
from the Edaravone anion to the peroxyl radical, halting lipid 
peroxidation. Pertinent to this, Wang and co-workers have 
shown that Edaravone inhibits the oxidation of unilamellar 
soybean phosphatidylcholine liposomal membranes [19]. As 
a strong antioxidant, Edaravone is a free radical scavenger, 
useful for protection against oxidative stress and neuronal 
apoptosis [20]. In the mouse focal ischemic model, the anti-
oxidant properties of Edaravone were postulated, crucial for 
the neuroprotective effects of Edaravone [21, 22]. In China 
and Japan, Edaravone alleviated the effects of cerebral is-
chemic stroke [23]. Edaravone efficiency has also been con-
firmed in the treatment of traumatic brain damage [24]. It is 
likely that Edaravone can have other effects than acting only 
as a free radical scavenger. Edaravone improves vascular 
blood flow through the up-regulation of endothelial nitric 
oxide synthase and reduction in LDL oxidation, which in 
turn results in an improvement in ischemic tissues. These 
findings were subjected to a critical assessment of Edaravone 
in acute ischemic stroke trials [25]. Edaravone suppressed 
ferroptosis in cystine–glutamate antiporter (xCT) - knockout 
mouse-derived embryonic fibroblasts, which usually die in 
normal cultivating conditions due to the depletion of intra-
cellular Cys and GSH [26]. 
1.4. Therapeutic Approach in ALS and Way Forward 
 The current treatment regimen for ALS is Riluzole which 
slows disease progression modestly and Edaravone recently 
approved by the FDA to slow ALS progression. There is 
evidence to support the efficacy of Edaravone in delaying 
definitive disease progression (the benefits of Edaravone 
therapy are maximised after early ALS diagnosis [27]. The 
most recent investigation showed that Edaravone alone was 
not effective in unselected ALS patients [28] as well as in 
selected patients in a randomised double-blind trial and in 
patients with advanced disease [29]. 
 The multifaceted mechanisms of ALS initiation and pro-
gression indicate that a suitable therapeutic approach must be 
complex. Single components have little chance to be thera-
peutically effective in such a disease. One observation re-
garding the role of uric acid in cerebrospinal fluid [30] was 
followed up [31-33] indicating that high urate levels corre-
late with improved survival in ALS patients and that urate 
was neuroprotective in several models of neurodegeneration 
[33-35]. These findings provide the basis for larger clinical 
trials of inosine testing as a potential therapy for disease 
modification for ALS [36]. The conclusion is that they 
demon-strate safety, tolerability, and urate-elevating 
capability of the urate precursor inosine in ALS patients. 
Taken together with convergent epidemiological, 
biological, and clinical data pointing to urate as a 
potential neuroprotectant, the study supports clinical trials 
aimed to test the ability of inosine to slow clinical ALS 
progression [36]. The next phase should be a combination 
of therapeutics such as Edaravone. Edavarone has some 
additional effects among antioxidative ones. Cell damage 
during ischemic reperfusion occurs via the opening of 
mitochondrial permeability transition pores, which leads to 
overflow of ROS and calcium ions. Edara-vone reduces 
calcium ion-induced mitochondrial swelling in the rat brain. 
In addition, Edaravone acts as an apoptotic
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shield within ischemic neurons by reducing the expression of 
Fas-associated death domain protein, death-associated pro-
tein and caspase-8 immuno-reactivity in a rat MCAO model 
[37]. During cerebral ischemia provoked by calcium ions,
ROS overload, and iNOS expression, Edaravone attenuated
apoptosis and inflammation. Edaravone has also been used
in combination therapy with other thrombolytic drugs to pro-
tect the integrity of neurons and blood vessels.
1.5. The Molecular Base for Combinatorial Approach in 
ALS Therapy 
Motor neurons challenged by an increased presence of 
iron protect themselves by oxidising ferrous ions (Fe2+) to 
ferric ions (Fe3+) in the extra-cellular space and depositing 
them in the precentral gyruses gray matter (Fig. 1) [6]. Fe3+ 
may be reduced to Fe2+ by ascorbate. Electron paramagnetic 
resonance spectroscopy identified ascorbyl radicals in the 
CSF from ALS patients, but not in controls [5]. The addition 
of H2O2 to CSF from ALS patients provoked the further 
formation of ascorbyl radicals and the formation of •OH rad-
icals ex vivo. In contrast, the addition of uric acid to CSF 
from ALS patients ex vivo diminished the production of •OH 
radicals. Fe2+ may participate in the Fenton reaction extracel-
lularly in CSF of ALS patients as H2O2 is continuously re-
leased by neurons (Fig. 1).  
This reaction generates •OH radicals which cause lipid 
peroxidation of cell membranes. Fe3+ from CSF can be ab-
sorbed in motor neurons by the transferrin receptor (TFR1) 
and reduced to Fe2+ by divalent metal (ion) transporter 1 
(DMT1). Thus Fe2+ may promote the Fenton reaction inside 
motor neuron cells inducing intracellular lipid peroxidation. 
Under conditions of inadequate quantities of glutathione and 
low GPx4 (selenium-dependent) activity, the induction of 
cell death termed ferroptosis may occur.  
 Even if Edaravone prevents ferroptosis and there is ade-
quate GSH and GPx4 activity, the induction of apoptosis is 
still possible. Oxidation products promote both DNA and 
protein damage and cause activation of p53-dependent apop-
tosis which can also lead to neuron cell death. This could 
explain the efficiency of Edaravone treatment of ALS in the 
early stages of disease more so than in later stages of the 
disease. 
 Ascorbate has unfavourable effects in ALS patients as it 
promotes pro-oxidative circulation of iron between CSF and 
iron deposits in the cortex [38]. In 2009, Keizman and col-
leagues found that ALS patients had lower serum uric acid 
levels compared with healthy individuals [39]. The de-
creased uric acid levels correlated with the rate of disease 
progression, supporting the role of oxidative stress in the 
induction and propagation of the disease. 
 Various forms of regulated cell death may exist in popu-
lations of motor neurons, one being dominant when some 
specific mutation is the cause of disease. Our published work 
suggested that the misfolded L144P SOD1 mutant protein 
forms pores that render lipid membranes permeable to ionic 
flow [40]. Such long-term cellular membrane disturbance 
could cause irreversible damage to neuronal cells and cell 
death in ALS patients through a variety of mechanisms in-
Fig. (1). A scheme showing the key steps of ferroptosis induction in motor neurons. A possible role of Edaravone in ferroptosis inhibition is 
presented. Asc – Ascorbate; DMT1-Divalent metal (ion) transporter 1; GSH-Glutathione; GSSG-oxidised glutathione; •OH-hydroxyl radical; 
TFR1-Transferrin receptor; UA-uric acid; xCT-cystine–glutamate antiporter. (A higher resolution / colour version of this figure is available in 
the electronic copy of the article). 
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cluding defective calcium ion buffering capacity and in-
creased metabolic demands causing oxidative stress and mi-
tochondrial dysfunction leading to another form of cell death 
in ALS. Even wild-type superoxide dismutase type 1 protein, 
normally active in healthy individuals as a soluble metallo-
enzyme, can be transformed with respect to its struc-
ture/function into a “toxic channel” by mutation or by envi-
ronmental stress [41]. Furthermore, these toxic channels in 
the lipid membranes of motor neurons (such as the outer cell 
and mitochondrial membranes) can create ionic imbalances 
(such as calcium ion overload) resulting in the neurotoxicity 
that characterises ALS. Evidence from in vitro, cell culture, 
and in vivo studies has provided strong evidence to support 
the involvement of a prion-like mechanism in ALS [42]. 
 Motor neuron degeneration underlies motor neuron diseas-
es such as ALS. Therefore, ferroptosis generally refers to an 
iron-dependent, non-apoptotic form of regulated cell death. 
Ferroptosis inhibition may be essential for good motor neuron 
health and survival in vivo. Deletion of GPx4 induces ferrop-
tosis-induced motor neuron degeneration and paralysis, 
strongly indicating that GPx4 is crucial for motor neuron 
health and survival in vivo [43]. The presumption is that fer-
roptosis requires three critical events: (1) accumulation of re-
dox-active iron, (2) glutathione depletion, and (3) lipid peroxi-
dation. It is proposed that these three events must occur simul-
taneously as inhibiting just one prevents ferroptosis. The three 
events are hypothesised to amplify in severity through positive 
feedback loops. Therefore, the cause of death in ferroptosis is 
the synergistic combination of antioxidant depletion, iron tox-
icity, and membrane denaturation. Edaravone, an intracellular 
antioxidant, may prevent ferroptosis in motor neurons and it 
may be its primary mode of action.  
CONCLUSION 
 The multifaceted mechanisms underlying both the initia-
tion and progression of ALS indicate that a suitable thera-
peutic approach must be wide-reaching. The mechanism of 
Edravone action in ALS is the prevention of oxidative dam-
age in intracellular lipid membranes which prevents ferrop-
tosis (a form of programmed cell death) which can kill motor 
neurons. It is not likely to influence the wide ALS popula-
tion. Early stage sporadic ALS patients may react to 
Edravone treatment before pathophysiological processes are 
advanced and before the induction of other forms of motor 
neuron programmed cell death. Edaravone may be one com-
ponent within a complex treatment regime for ALS. If so, 
Edaravone could be a new player in a complex playground. 
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